- Home
- SDA vs TLSA Comparison
SDA vs TLSA Comparison
Compare SDA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDA | TLSA |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.5M | 182.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SDA | TLSA |
|---|---|---|
| Price | $2.10 | $1.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.75 | N/A |
| AVG Volume (30 Days) | 73.6K | ★ 420.5K |
| Earning Date | 12-18-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,272,000.00 | N/A |
| Revenue This Year | $10.86 | N/A |
| Revenue Next Year | $13.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.69 | N/A |
| 52 Week Low | $1.54 | $0.63 |
| 52 Week High | $10.61 | $2.60 |
Technical Indicators
Market Signals| Indicator | SDA | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 58.37 | 42.23 |
| Support Level | $1.98 | $1.45 |
| Resistance Level | $2.09 | $1.62 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 100.00 | 44.23 |
Price Performance
Historical ComparisonAbout SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.